XNCR - Xencor Inc
IEX Last Trade
20.86
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 09:01:15 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$20.86
2.54
0.11%
Fundamental analysis
8%
Profitability
0%
Dept financing
5%
Liquidity
75%
Performance
1%
Performance
5 Days
-3.63%
1 Month
-3.52%
3 Months
18.98%
6 Months
20.11%
1 Year
15.23%
2 Year
-6.29%
Key data
Stock price
$20.86
DAY RANGE
$20.86 - $23.40
52 WEEK RANGE
$16.10 - $27.24
52 WEEK CHANGE
$15.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Bassil I. Dahiyat
Region: US
Website: xencor.com
Employees: 280
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xencor.com
Employees: 280
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Xencor, Inc. focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Its product candidates include Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma.
Recent news